Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 17/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13441991 | 0.92 | MAPKAPK2 (0.34) | TBK1MAPKAPK2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL13408194 | 0.88 | TBK1 (0.41) | TBK1PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL14283752 | 0.87 | PIK3CA (0.39) | MAPKAPK2PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL13408186 | 0.84 | CDC7 (0.43) | TBK1PIK3CDPIK3R1PIK3CAPIK3CB | |
| Trifluoroacetic Acid SCHEMBL3613213 | 0.83 | TBK1 (0.36) | TBK1 | |
| SCHEMBL4005876 | 0.83 | PIK3CA (0.36) | MAPKAPK2PIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL13442016 | 0.80 | MYLK4 (0.36) | TBK1MAPKAPK2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL13408196 | 0.80 | PIM1 (0.43) | TBK1MAPKAPK2 | |
| Trifluoroacetic Acid SCHEMBL3618387 | 0.79 | CDC7 (0.38) | TBK1 | |
| SCHEMBL13408197 | 0.79 | PIM1 (0.42) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | claimed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | TBK1 4542/4885MAPKAPK2 4395/4885PIK3CD 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.